Market news

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Shareholders of Phibro Animal Health would probably like to forget the past six months even happened. The stock dropped 38.5% and now trades at $34.11. This may have investors wondering how to approach the situation.

TEANECK, N.J., September 09, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference.

Phibro Animal Health earnings and guidance set the tone Phibro Animal Health (PAHC) drew investor attention after issuing earnings guidance for the fiscal year ending June 30, 2027, alongside reporting fourth quarter and full year 2026 results. The company now projects 2027 net sales of US$1.55b to US$1.60b and net income of US$122 million to US$132 million. Expected diluted EPS is US$2.98 to US$3.22. These figures follow 2026 sales of US$1,518.09 million and net income of US$99.72...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PAHC’s Zoetis MFA acquisition boosts animal-health growth via vaccines and companion animals. Click for more on PAHC stock.

Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi

Motley Fool Press Release.

Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call

Phibro Animal Health Corp (PAHC) posts record FY2026 results with 39% adjusted EBITDA growth, while navigating Brazil regulatory uncertainty and executing strategic manufacturing optimization.

Phibro (PAHC) delivered earnings and revenue surprises of +18.06% and +8.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year to $396.7 million. The company’s full-year revenue guidance of $1.58 billion at the midpoint came in 1.9% above analysts’ estimates. Its non-GAAP profit of $0.85 per share was 17.1% above analysts’ consensus estimates.

TEANECK, N.J., August 26, 2026--Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Phibro Animal Health (PAHC) reported fiscal Q4 adjusted earnings late Wednesday of $0.85 per diluted

Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be reporting earnings this Wednesday afternoon. Here’s what investors should know.

Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Phibro Animal Health has delivered a very strong 149.1% return over the past 3 years, yet the current valuation checks paint a more mixed picture rather than a straightforward bargain or clear overpricing. Phibro Animal Health's 149.1% three year return shows shareholders have already seen very large gains, which raises the bar for any new buyers looking for further upside. Future expectations around margins and cash flow from its animal health portfolio can support today’s price. However,...

Phibro Animal Health (PAHC) is approaching a key disclosure date, with fourth quarter and full year 2026 results scheduled for release on August 26 after the market close, followed by a conference call on August 27. See our latest analysis for Phibro Animal Health. The upcoming earnings announcement comes after a mixed year for Phibro Animal Health, with the share price at US$35.44, a 1 month share price return of 7.23% and year to date share price return declining 4.99%, while the 3 year...

Detailed price information for Cava Group Inc (CAVA-N) from The Globe and Mail including charting and trades.

TEANECK, N.J., July 28, 2026--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, , payable on September 23, 2026, to stockholders of record at the close of business on September 2, 2026.

Phibro Animal Health stock has quietly posted a very large 3 year gain while still screening as undervalued on broader checks, leaving investors weighing a strong share price run against a set of metrics that point to remaining value support. Over the past 3 years, Phibro Animal Health has returned about 137.7%, which puts recent short term moves into the context of a very strong multi year run. Expectations around the company’s ability to sustain and grow cash flows from its animal health...

Index removal puts Phibro Animal Health in a different spotlight Phibro Animal Health (PAHC) was recently removed from several Russell indices, including the Russell 3000E and Microcap benchmarks. This type of change can alter how certain institutional investors gain exposure to the stock. Index changes like this can trigger adjustments by funds that track or reference those benchmarks. They do not, however, directly affect Phibro Animal Health’s operations, revenue sources, or long history...

Phibro Animal Health Corporation (NasdaqGM:PAHC) has been removed from several Russell indexes, including the Russell Microcap and Russell 3000E. The changes affect both the core and growth benchmarks in the Russell family of indexes. This index removal alters the stock’s exposure to index-tracking funds and some institutional investors. Phibro Animal Health focuses on animal health and nutrition products, a sector that often tracks broader trends in protein consumption and livestock...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Investors need to pay close attention to PAHC stock based on the movements in the options market lately.